Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
OwnerUgur SAHIN, Steve PASCOLO +1inventors
InventorsUgur SAHIN, Steve PASCOLO, Tobias WEISS
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a multifunctional cell recombinantly expressing an immune receptor and two or more cytokines, wherein the cell comprises one or more exogenous RNA molecules encoding the immune receptor and the two or more cytokines. The expression in the multifunctional cell is transient. Also disclosed herein are methods of using such a multifunctional cell in the treatment of diseases and disorders characterized by expression of a protein or antigen that is able to be bound by the immune receptor, such as cancer, for example glioblastoma. Also disclosed herein are methods for the production of such a multifunctional cell.
Claims73
A multifunctional cell recombinantly expressing an immune receptor and two or more cytokines, wherein the cell comprises one or more exogenous RNA molecules encoding the immune receptor and the two or more cytokines.
The multifunctional cell according to any one of claims 1 to 14 which is a CD8+ T cell.
A multifunctional cell recombinantly expressing an immune receptor and two or more cytokines for use in a method of treating a disease or disorder in a patient characterized by the expression of an antigen to which the immune receptor binds, wherein the cell comprises one or more exogenous RNA molecules encoding the immune receptor and the two or more cytokines, said method comprising administering the multifunctional cell to the patient, preferably wherein the patient is a human.
A cytotoxic T cell expressing a chimeric antigen receptor (CAR) capable of binding to a NKG2D ligand, interleukin-12, and interferon-α2 for use in a method of treating glioblastoma, wherein the cytotoxic T cell comprises three exogenous mRNA molecules, the first encoding the CAR, the second encoding interleukin-12, and the third encoding interferon-α2.
A method for producing a multifunctional cell expressing an immune receptor and two or more cytokines, said method comprising transfecting a mononuclear cell with one or more exogenous RNA molecules encoding the immune receptor and the two or more cytokines to produce a multifunctional cell expressing the immune receptor and the two or more cytokines.
A method of treating a disease or disorder in a patient comprising administering to the patient a multifunctional cell recombinantly expressing an immune receptor and two or more cytokines, wherein the disease or disorder is characterized by the expression of an antigen to which the immune receptor binds, wherein the cell comprises one or more exogenous RNA molecules encoding the immune receptor and the two or more cytokines, preferably wherein the patient is a human.
One or more exogenous RNA molecules encoding an immune receptor and two or more cytokines for use in a method of treating a disease or disorder in a patient, said method comprising administering to the patient the one or more exogenous RNA molecules, wherein the disease or disorder is characterized by the expression of an antigen to which the immune receptor binds, preferably wherein the patient is a human
A method of treating cancer in a patient comprising administering to the patient one or more exogenous RNA molecules encoding an immune receptor and two or more cytokines, wherein the cancer is characterized by the expression of a cancer antigen to which the immune receptor binds, preferably wherein the patient is a human.
Dependencies are inferred from the claim text.